American Society Of Clinical Oncology

Circulating tumor DNA-based detection of molecular residual disease appeared to be highly prognostic of patient outcomes, according to data presented at ASCO Gastrointestinal Cancers Symposium.

Men with low-risk prostate cancer chose active surveillance more often than surgery or radiation when urologists recommended that course of action, according to study results published in Cancer.

Glecirasib exhibited antitumor activity among patients with pancreatic ductal adenocarcinoma and other solid tumors harboring the KRAS G12C mutation variant, study findings presented at ASCO Gastrointestinal Cancers Symposium showed.

To address ongoing chemotherapy drug shortages, ASCO convened a multidisciplinary panel of oncologists, ethicists and patient advocates to expedite clinical guidance for navigating care where rationing or alternative therapies are needed.

Oncologists in the U.S. reported a worsening of burnout and lower satisfaction with work-life balance over the last decade, according to a study presented at ASCO Quality Care Symposium.

City of Hope received a $100M philanthropic gift to create a national integrative oncology program that will combine and optimize Eastern and Western medicine to improve outcomes and quality of life for patients with cancer and survivors.

ASCO released a research statement outlining new recommendations regarding the appropriate assessment of ovarian toxicity in cancer clinical trials.

ASCO and Society for Integrative Oncology published a guideline that recommends mindfulness-based interventions and other integrative approaches for management of cancer-related anxiety and depression.

Hagop Kantarjian, MD, is internationally recognized as a pioneer in the medical field.

Abstracts of randomized phase 3 clinical trials in gastrointestinal oncology frequently use subjective minimizing language to characterize serious toxicities, according to results of a systematic review presented at ASCO Annual Meeting.